Olaparib beyond progression compared to platinum chemotherapy after secondary cytoreductive surgery in recurrent ovarian cancer patients. The phase III randomized, open label MITO 35b study: a project of the MITO-MANGO groups.
Latest Information Update: 20 Jun 2022
At a glance
- Drugs Olaparib (Primary) ; Carboplatin; Cisplatin; Doxorubicin; Gemcitabine; Paclitaxel
- Indications Adenocarcinoma; Endometrial cancer; Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Therapeutic Use
- Acronyms MITO 35B
- 06 Jun 2022 Trial design, published in the International Journal of Gynecological Cancer
- 25 Aug 2021 Planned End Date changed to 17 Jul 2025.
- 25 Aug 2021 New trial record